LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Galili, Uri

Immunology

2013  Volume 140, Issue 1, Page(s) 1–11

Abstract: Anti-Gal is the most abundant natural antibody in humans, constituting ~ 1% of immunoglobulins ... Anti-Gal is naturally produced also in apes and Old World monkeys. The ligand of anti-Gal is ... present as a major carbohydrate antigen in non-primate mammals, prosimians and New World monkeys. Anti-Gal ...

Abstract Anti-Gal is the most abundant natural antibody in humans, constituting ~ 1% of immunoglobulins. Anti-Gal is naturally produced also in apes and Old World monkeys. The ligand of anti-Gal is a carbohydrate antigen called the 'α-gal epitope' with the structure Galα1-3Galβ1-4GlcNAc-R. The α-gal epitope is present as a major carbohydrate antigen in non-primate mammals, prosimians and New World monkeys. Anti-Gal can contributes to several immunological pathogeneses. Anti-Gal IgE produced in some individuals causes allergies to meat and to the therapeutic monoclonal antibody cetuximab, all presenting α-gal epitopes. Aberrant expression of the α-gal epitope or of antigens mimicking it in humans may result in autoimmune processes, as in Graves' disease. α-Gal epitopes produced by Trypanosoma cruzi interact with anti-Gal and induce 'autoimmune like' inflammatory reactions in Chagas' disease. Anti-Gal IgM and IgG further mediate rejection of xenografts expressing α-gal epitopes. Because of its abundance, anti-Gal may be exploited for various clinical uses. It increases immunogenicity of microbial vaccines (e.g. influenza vaccine) presenting α-gal epitopes by targeting them for effective uptake by antigen-presenting cells. Tumour lesions are converted into vaccines against autologous tumour-associated antigens by intra-tumoral injection of α-gal glycolipids, which insert into tumour cell membranes. Anti-Gal binding to α-gal epitopes on tumour cells targets them for uptake by antigen-presenting cells. Accelerated wound healing is achieved by application of α-gal nanoparticles, which bind anti-Gal, activate complement, and recruit and activate macrophages that induce tissue regeneration. This therapy may be of further significance in regeneration of internally injured tissues such as ischaemic myocardium and injured nerves.
MeSH term(s) Animals ; Antibodies, Heterophile/immunology ; Autoimmunity ; Cancer Vaccines/immunology ; Chagas Disease/immunology ; Epitopes/immunology ; Graves Disease/immunology ; Humans ; Hypersensitivity/immunology ; Immunity, Innate ; Immunoglobulin E/immunology ; Mammals/immunology ; Regeneration/immunology ; Transplantation Immunology ; Transplantation, Heterologous ; Trisaccharides/immunology ; Viral Vaccines/immunology ; Wound Healing/immunology
Chemical Substances Antibodies, Heterophile ; Cancer Vaccines ; Epitopes ; Trisaccharides ; Viral Vaccines ; alpha-galactosyl epitope ; Immunoglobulin E (37341-29-0)
Language English
Publishing date 2013-04-11
Publishing country England
Document type Journal Article ; Review
ZDB-ID 80124-0
ISSN 1365-2567 ; 0019-2805 ; 0953-4954
ISSN (online) 1365-2567
ISSN 0019-2805 ; 0953-4954
DOI 10.1111/imm.12110
Shelf mark
Ud II Zs.181: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top